Table 1. Voxel-based studies included in the meta-analysis.
| Voxel-based Studies | Disorder Type | Mean | Global tissue | Sample Size | Mean Age | ||
| IQ | Difference | Subjects | Controls | Subjects | Controls | ||
| Autism Spectrum Disorders | |||||||
| Abell et al., 1999 | Asperger | >70 | n/a | 15 | 15 | 28.8 | 25 |
| Boddaert et al., 2004 | Autism | <70 | n/a | 21 | 12 | 9.3 | 10.8 |
| Bonilha et al., 2008 | Autism | <70 | n/a | 12 | 16 | 12.4 | 13.2 |
| Brieber et al., 2007 | HFA, Asperger | >70 | No | 15 | 15 | 14.2 | 13.3 |
| Craig et al., 2007 | HFA, Asperger | >70 | No | 14 | 19 | 37.9 | 35 |
| Ecker et al., 2009 | HFA | >70 | No | 22 | 22 | 27 | 28 |
| Hyde et al., 2009 | HFA | >70 | No | 15 | 13 | 22.7 | 19.2 |
| Ke et al., 2008 | HFA | >70 | No | 17 | 15 | 10 | 9.7 |
| Kwon et al., 2004 | HFA, Asperger | >70 | n/a | 20 | 13 | 14 | 13.6 |
| McAlonan et al., 2002 | Asperger | >70 | No | 21 | 24 | 32 | 33 |
| McAlonan et al., 2008 | HFA, Asperger | >70 | No | 33 | 55 | 11.4 | 10.7 |
| Roja et al., 2006 | HFA | >70 | No | 24 | 23 | 22.6 | 21.4 |
| Toal et al., 2009 | Autism, HFA | >70 | No | 65 | 33 | 31 | 32 |
| Waiter et al., 2004 | HFA, Asperger | >70 | >GM | 16 | 16 | 15.4 | 15.5 |
| Wilson et al., 2009 | HFA | >70 | No | 10 | 10 | 30 | 29.4 |
| 320 | 301 | 21.2 | 20.7 | ||||
| Schizophrenia | |||||||
| Chua et al., 2007 | NN-FES | >70 | <GM | 26 | 38 | 32 | 33 |
| Ebdrup et al. 2010 | NN-FES | >70 | No | 29 | 43 | 25.7 | 26.9 |
| Kasparek et al., 2007 | NT-FES (7 weeks) | n/a | No | 49 | 127 | 23.7 | 24.1 |
| Lui et al., 2009 | NN-FES | >70 | n/a | 68 | 68 | 24.7 | 24.7 |
| Meda et al., 2008 (WPIC) | NN-FES | n/a | No | 22 | 21 | 25 | 26.2 |
| Molina et al. 2010 | NT-FES (<1 week) | >70 | No | 30 | 40 | 25.8 | 29.4 |
| Salgado-Pineda et al., 2003 | NN-FES | n/a | No | 13 | 13 | 23.8 | 23.4 |
| Schaufelberger et al., 2007 | NT-FES (<18 weeks) | >70 | No | 62 | 94 | 27.6 | 30.2 |
| Venkatasubramanian, 2010 | NN-FES | >70 | <GM | 30 | 27 | 30.1 | 27.4 |
| Witthaus et al, 2009 | NT-FES (<2 weeks) | >70 | No | 23 | 29 | 26.4 | 25.7 |
| 352 | 500 | 26.5 | 27.1 | ||||
Global tissue difference is any significant total grey matter difference compared to controls (HFA, high-functioning autism; NN-FES, neuroleptic-naïve first episode schizophrenia patients; NT-FES, neuroleptic-treated first episode schizophrenia patients; GM grey, matter).